RE: $FHTX & DS - Interesting paper by a group at NIBR testing their BRM/BRG1 inhibitor tool compound in a variety of AML cell lines, noted cell-line specific responses (differentiation/apoptosis). Good weekend reading material - https://t.co/y4NNwVJpl0
$FHTX Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia... https://t.co/nIhnilzkHo
👩🔬👨🔬 Led by Dr. Rago, researchers at Novartis Institute (@NovartisScience) evaluated the activity of dual BRG1/BRM ATPase inhibitor and observed 🤔 that #hematopoietic cancer cell lines were among the most sensitive compared to other lineages. @MCR_AACR
SWI/SNF dependency in leukemia&Dual BRG1/BRM ATPase Inhibitors https://t.co/FfJHPULFCO
Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia https://t.co/c9JTo4yPzy https://t.co/Scr4gUbEGC
New article: Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia https://t.co/GNRJOVnBnI #AML #leusm #hematology https://t.co/X2U4aqjfWD